AI lets chemists design molecules by simply describing them

Voyager Therapeutics presented three-month GLP toxicology data at ASGCT showing its investigational tau-silencing gene therapy VY1706 was well tolerated and reduced tau protein up to 64% in key brain regions of non-human primates 13 weeks after a single IV dose. The GLP study reported no adverse cli…